Melatonina
Anno: 2007
-
Riferimento:Am J Ther. 2007 Jan-Feb;14(1):113-5.Azione della melatonina:After 2 months the patient had a partial response, and after 5 months he achieved a complete response.Target:Treatment had very good tolerance.
-
Riferimento:Crit Rev Oncog. 2007 Dec;13(4):303-28Azione della melatonina:Both human epidemiological and experimental studies on animals have documented that a potential negative consequence of chronodisruption and nocturnal melatonin inhibition is cancer initiation and growth (breast, prostate, endometrial, and colorectal).Target:LAN
-
Riferimento:Cell Cycle. 2007 Jun 1;6(11):1329-31.Azione della melatonina:Here we speculate on the molecular pathways that may couple the circadian machinery to breast cancer.Target:Circadian clock
-
Riferimento:Pathol Biol (Paris). 2007 Apr-May;55(3-4):201-4.Azione della melatonina:Confirmed in human the anticancer properties of MLT (20 mg/day orally), which may enhance the efficacy of the chemotherapies in colorectal cancer patients.Target:MLT may play anticancer activity.
-
Riferimento:J Pineal Res. 2007 Apr;42(4):403-10.Azione della melatonina:Female mice were treated with CdCl(2) (2-3 mg/kg, i.p.), melatonin (10 microg/mL in drinking water), CdCl(2) + melatonin, or diluents. The effects of Cd are partially inhibited by melatonin.Target:Cd-induced carcinogenicity.
-
Riferimento:Sleep Med. 2007 Sep;8(6):613-22.Azione della melatonina:Female shiftworkers compared to non-shiftworkers are more likely to report menstrual irregularity and longer menstrual cycles.Target:Circadian disruption.
-
Riferimento:Oncol Rep. 2007 Apr;17(4):947-53.Azione della melatonina:Melatonin inhibits both aromatase activity as a selective estrogen enzyme modulator. 20% at 1 nM; 40% at 10 microM Mlt concentrations.Target:MT1 melatonin receptor.
-
Riferimento:Eur J Pharmacol. 2007 Mar 29;560(1):17-22.Azione della melatonina:A combination of valproic acid (0.5, 1.0 or 5 mM) and melatonin (1 or 10 nM) suggests that a similar approach may be beneficial in breast cancer.Target:MT1 Mlt receptor mRNA.
-
Riferimento:Chem Res Toxicol. 2007 Dec;20(12):1947-53.Azione della melatonina:N-acetylcysteine, melatonin, reduced lipoic acid and resveratrol can inhibit the formation of depurina- ting estrogen-DNA adducts.Target:Estradiol (E2)-3,4-quinone (Q).
-
Riferimento:J Behav Med. 2007 Feb;30(1):45-58.Azione della melatonina:Forty percent of the women with breast cancer had stage 2 disease and they were an average of 1.36years post-diagnosis. Women with breast cancer had significantly higher levels of disturbance on all the psychological indices.Target:Dysregulations across systems in breast cancer patients.